NAD Supplementation for Brain Health in Aging
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if taking Nicotinamide Riboside (NR), a form of Vitamin B3, can improve brain health and memory in older adults aged 60-85 by boosting a molecule called NAD that helps with energy and cell health. Nicotinamide Riboside (NR) is a precursor to NAD+, which has been identified as a promising treatment strategy for age-related cognitive decline and other conditions.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot take other NAD enhancers like Nicotinamide riboside or nicotinamide mononucleotide within 4 weeks before starting the trial.
Is NAD supplementation safe for humans?
Nicotinamide riboside (NR), a form of NAD supplementation, has been shown to be generally safe in humans. Studies have found no significant differences in adverse events between NR and placebo groups, and it is recognized as safe for use in foods and dietary supplements. However, high doses of a related compound, nicotinamide, may pose potential risks for long-term use.12345
How does the drug nicotinamide riboside differ from other treatments for brain health in aging?
Nicotinamide riboside is unique because it boosts NAD+ levels, which are important for energy metabolism and brain function, and it has shown potential in improving cognitive function and reducing neurodegenerative markers in aging and Alzheimer's models. Unlike other treatments, it is a precursor to NAD+ and can be taken orally, making it a convenient option for enhancing brain health.14678
What data supports the effectiveness of the treatment Nicotinamide riboside for brain health in aging?
Research shows that Nicotinamide riboside (NR) can increase NAD+ levels, which are important for energy metabolism, and improve brain function in some animal models of neurodegeneration. In humans, NR supplementation has been shown to raise NAD+ levels and modify biomarkers related to neurodegenerative diseases, suggesting potential benefits for brain health.14678
Who Is on the Research Team?
Andriy Yabluchanskiy, MD, PhD
Principal Investigator
University of Oklahoma
Are You a Good Fit for This Trial?
This trial is for people aged 60 to 85 who can read and write in English, have good enough vision and hearing to participate, and can give informed consent. It's not for those with recent severe strokes, major uncontrolled psychiatric conditions, substance abuse issues, active brain diseases or poor kidney function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Nicotinamide Riboside (NR) or placebo daily for 8 weeks to assess effects on neurovascular coupling and endothelial function
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nicotinamide riboside
- Placebo
Nicotinamide riboside is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor
University of Pennsylvania
Collaborator
Elysium Health
Industry Sponsor
Oklahoma Medical Research Foundation
Collaborator